Ó³»­´«Ã½

Huggins DJ, Baell J, Brennan PE, Burgin A, Scott DE. The benefits of translating biomedical research at drug discovery institutes. Nature reviews. Drug discovery. 2024. doi:10.1038/d41573-024-00142-z

Arbesfeld JA, Da EY, Stevenson JS, et al. Mapping MAVE data for use in human genomics applications. bioRxiv : the preprint server for biology. 2024. doi:10.1101/2023.06.20.545702

Kwon S, Safer J, Nguyen DT, et al. Genomics 2 Proteins portal: a resource and discovery tool for linking genetic screening outputs to protein sequences and structures. Nature methods. 2024. doi:10.1038/s41592-024-02409-0

Bazua-Valenti S, Brown MR, Zavras J, et al. Disrupted uromodulin trafficking is rescued by targeting TMED cargo receptors. The Journal of clinical investigation. 2024;134(24). doi:10.1172/JCI180347

Subramanian A, Vernon KA, Zhou Y, et al. Protective role for kidney TREM2 macrophages in obesity- and diabetes-induced kidney injury. Cell reports. 2024;43(6):114253. doi:10.1016/j.celrep.2024.114253

Meibom D, Wasnaire P, Beyer K, et al. BAY-9835: Discovery of the First Orally Bioavailable ADAMTS7 Inhibitor. Journal of medicinal chemistry. 2024. doi:10.1021/acs.jmedchem.3c02036

Placzek MS, Wilton DK, Weïwer M, et al. A Fast-Binding, Functionally Reversible, COX-2 Radiotracer for CNS PET Imaging. ACS central science. 2024;10(5):1105-1114. doi:10.1021/acscentsci.3c01564

Rauh U, Wei G, Serrano-Wu M, et al. BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models. Nature cancer. 2024. doi:10.1038/s43018-024-00814-0

Khandelwal NK, Gupta M, Gomez JE, et al. Structure and inhibition mechanisms of essential transporter efflux protein A. bioRxiv : the preprint server for biology. 2024. doi:10.1101/2024.09.04.611325

Rubinson DA, Tanaka N, de la Cruz FF, et al. Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers. Cancer discovery. 2024;14(5):727-736. doi:10.1158/2159-8290.CD-23-1138